Deep tissue depletion of B cells after CD19-CAR T-cell therapy may likely be based on the fact that (1) antigen binding and effector function are integrated into one and the same cell, (2) CD19-CAR T ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Previously, we have shown that MSC can abrogate plasmablast formation and induce IL-10 + and CD19 + CD38 high CD24 high B cells (11), which are the two ... To summarize, we show that immunological ...

Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...

We will cover first clinical results of applying anti-CD19 and anti-B cell maturation antigen CAR T cells for B cell ... anti-TNF antibodies (infliximab)) or by small molecules that mainly act on B ...

Chimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive results in patients with relapsed/refractory (R/R) B-cell malignancies, leading to their approval in ...

It has also been shown to activate, proliferate, and expand the number and function of natural killer cells ... NKTR vs placebo to enhance complete responses and durability following CD19-directed CAR ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for ...

A new study reveals that modifying the CUL5 gene enhances CAR-T cell therapy for leukemia and lymphoma. This improves cell ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.